Response to A+CHP by CD30 expression in the ECHELON-2 trial.

Ranjana H. Advani,Steven M. Horwitz,Swaminathan Padmanabhan Iyer,Nancy L. Bartlett,Won-Seog Kim,Hervé Tilly,David Belada,Tatyana Feldman,Árpád Illés,Eric D. Jacobsen,Andreas Huettmann,Pier Luigi Zinzani,Owen A. O'Connor,William L. Trepicchio,Harry H. Miao,Shangbang Rao,Matthew D. Onsum,Thomas Manley,Timothy M Illidge

Response to A+CHP by CD30 expression in the ECHELON-2 trial.

2019

Ranjana H. Advani
Steven M. Horwitz
Swaminathan Padmanabhan Iyer
Nancy L. Bartlett
Won-Seog Kim
Hervé Tilly
David Belada
Tatyana Feldman
Árpád Illés
Eric D. Jacobsen
Andreas Huettmann
Pier Luigi Zinzani
Owen A. O'Connor
William L. Trepicchio
Harry H. Miao
Shangbang Rao
Matthew D. Onsum
Thomas Manley
Timothy M Illidge

7538Background: Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30. The ECHELON-2 (E-2) study demonstrated significantly longer progression-free and overall survival with BV p...

Keywords:

Pathology
Conjugate
CD30
Oncology
Internal medicine
Brentuximab vedotin
Medicine
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations